Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On FOX 50 at 10: Storms rip trees from the ground Monday in NC. What residents in one neighborhood say they saw before a tree knocked out power
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
45.12
-0.03 (-0.07%)
Official Closing Price
Updated: 7:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Today 7:12 EDT
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.
Via
Benzinga
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
May 24, 2024
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
May 22, 2024
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.
Via
Benzinga
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
May 21, 2024
Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen,...
Via
Benzinga
Topics
Lawsuit
Whistleblower
Exposures
Financial
Legal
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
May 21, 2024
GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.
Via
Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
May 17, 2024
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.
Via
Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
May 16, 2024
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
May 14, 2024
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet.
Via
InvestorPlace
Amazon Pours ~$1.3B Investment Into French Operations: Report
May 13, 2024
Amazon's €1.2 billion investment marks a significant stride in bolstering its French presence, promising 3,000 new jobs. The move aligns with France's push for tech investment, showcased at the 'Choose...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
May 10, 2024
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported.
Via
Benzinga
Exposures
Product Safety
Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine
May 10, 2024
The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says.
Via
Investor's Business Daily
Exposures
Product Safety
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
May 09, 2024
Via
Benzinga
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
May 08, 2024
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?
May 02, 2024
Moderna is forming its first base in over a year. Could shares top a buy point on the company's sales beat?
Via
Investor's Business Daily
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
May 01, 2024
While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing.
Via
InvestorPlace
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
May 01, 2024
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix....
Via
Benzinga
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
May 01, 2024
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Forget the Fed. These 3 Stocks Will Soar No Matter What
April 29, 2024
The Fed's actions will have little impact on some stocks. Here are three excellent stocks that are likely to be unaffected by the Fed.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
April 26, 2024
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
What's Going On With Pfizer Stock On Thursday?
April 25, 2024
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
April 19, 2024
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory...
Via
Benzinga
Topics
Brexit
Exposures
Brexit
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
April 18, 2024
Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a focus shift to drug development, the move seeks funding for potential...
Via
Benzinga
GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
April 17, 2024
Lasting protection against shingles for adults over 50 with GSK's RZV vaccine. New data from ZOSTER-049 trial reveals over a decade of high efficacy. Plus, GSK's oral antibiotic, gepotidacin, shows...
Via
Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
April 11, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
April 08, 2024
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Via
The Motley Fool
CureVac, GS Partner Release Data On Influenza Vaccine Study
April 04, 2024
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...
Via
Benzinga
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
April 04, 2024
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.